▁Process 9.3125
▁Research 7.5703125
▁and 1.28515625
▁Development 1.0146484375
▁( 2.37890625
PR 0.300537109375
& 1.484375
D 0.005626678466796875
) 0.1163330078125
▁plays 6.70703125
▁a 0.44091796875
▁cru 2.48046875
cial 0.0011529922485351562
▁role 0.044769287109375
▁in 0.07666015625
▁the 1.021484375
▁ph 3.29296875
arma 0.0023288726806640625
ce 0.032806396484375
ut 3.170967102050781e-05
ical 0.0011997222900390625
▁industry 0.36328125
. 0.82470703125
▁It 2.533203125
▁is 0.85546875
▁responsible 1.9638671875
▁for 0.0035533905029296875
▁developing 1.294921875
▁efficient 6.48046875
▁and 0.58642578125
▁cost 1.1298828125
- 0.0161895751953125
effect 0.003383636474609375
ive 0.00017952919006347656
▁manufact 1.01171875
uring 0.00010502338409423828
▁processes 0.058074951171875
▁to 2.994140625
▁produce 0.12225341796875
▁active 4.0859375
▁ph 0.10321044921875
arma 0.00010454654693603516
ce 0.0007562637329101562
ut 6.0677528381347656e-05
ical 9.882450103759766e-05
▁ing 0.0091400146484375
red 2.8967857360839844e-05
ients 0.005401611328125
▁( 0.1400146484375
API 0.0015077590942382812
s 0.1346435546875
) 0.38525390625
▁and 0.122314453125
▁drug 2.185546875
▁products 0.2237548828125
. 0.118408203125
▁PR 2.025390625
& 0.0010843276977539062
D 0.00045561790466308594
▁influ 10.515625
ences 4.8160552978515625e-05
▁the 0.7509765625
▁drug 3.763671875
▁development 0.456298828125
▁tim 4.14453125
eline 0.2093505859375
▁by 2.05078125
▁optim 2.810546875
izing 0.0706787109375
▁the 0.68994140625
▁manufact 1.2392578125
uring 0.00539398193359375
▁process 0.140380859375
▁in 4.42578125
▁parallel 3.638671875
▁with 0.130126953125
▁the 0.53662109375
▁clin 1.451171875
ical 0.0005726814270019531
▁development 0.8193359375
▁of 1.548828125
▁a 1.548828125
▁new 1.7548828125
▁chemical 4.97265625
▁entity 0.005584716796875
▁( 0.326171875
N 0.001674652099609375
CE 0.0003154277801513672
). 0.189208984375
▁This 2.142578125
▁parallel 5.74609375
▁processing 4.44921875
▁acceler 5.203125
ates 0.0010213851928710938
▁the 0.202880859375
▁overall 3.65234375
▁tim 1.9892578125
eline 0.03082275390625
▁from 4.7109375
▁drug 1.57421875
▁discovery 0.169921875
▁to 0.0675048828125
▁market 1.0927734375
. 2.3828125
▁▁▁ 15.3671875
<0x0A> 2.45703125
<0x0A> 0.87646484375
The 2.35546875
▁main 3.4921875
▁sections 7.93359375
▁within 4.62890625
▁PR 0.81494140625
& 0.0034961700439453125
D 0.0008835792541503906
▁include 1.2919921875
▁process 1.9296875
▁research 2.078125
, 0.2998046875
▁process 0.76318359375
▁development 0.1749267578125
, 0.0931396484375
▁and 0.80517578125
▁pilot 2.82421875
▁plant 0.24755859375
▁operations 1.0908203125
. 0.0596923828125
▁Process 0.94580078125
▁research 0.06439208984375
▁focus 1.794921875
es 0.0006632804870605469
▁on 0.0019092559814453125
▁developing 1.6904296875
▁innov 2.716796875
ative 0.0011997222900390625
▁manufact 1.46875
uring 5.3882598876953125e-05
▁processes 0.409423828125
▁for 1.8583984375
▁APIs 1.30859375
▁and 0.1131591796875
▁drug 0.055328369140625
▁products 0.0182952880859375
. 0.342529296875
▁They 6.31640625
▁aim 4.09765625
▁to 0.0171966552734375
▁design 5.2109375
▁synth 6.35546875
etic 0.170654296875
▁routes 0.53125
, 1.2080078125
▁identify 2.22265625
▁critical 3.1484375
▁process 0.9404296875
▁parameters 0.1326904296875
, 0.230224609375
▁and 0.09393310546875
▁optimize 0.97412109375
▁reaction 2.638671875
▁conditions 0.0821533203125
. 0.6123046875
▁Process 0.66259765625
▁development 0.039794921875
▁further 4.359375
▁scales 5.7578125
▁up 0.2164306640625
▁and 4.0625
▁optim 1.8828125
izes 0.0007414817810058594
▁the 0.284912109375
▁processes 1.6689453125
▁developed 0.494140625
▁by 1.556640625
▁process 0.34326171875
▁research 0.00295257568359375
. 0.62646484375
▁They 2.064453125
▁determine 4.94140625
▁the 0.12939453125
▁critical 4.02734375
▁process 1.0830078125
▁parameters 0.07989501953125
▁and 1.02734375
▁specific 6.9375
ations 0.0230560302734375
▁to 3.318359375
▁control 4.40234375
▁vari 5.796875
ability 0.0188751220703125
. 1.4375
▁Pil 0.89013671875
ot 0.0002770423889160156
▁plant 0.055328369140625
▁operations 0.018768310546875
▁verify 4.21875
▁the 0.275390625
▁robust 2.609375
ness 0.00799560546875
▁of 0.5859375
▁the 0.09259033203125
▁optimized 3.318359375
▁process 0.8369140625
▁at 3.08984375
▁a 1.3603515625
▁larger 0.87060546875
▁scale 0.0223846435546875
. 0.59814453125
▁They 1.662109375
▁produce 3.154296875
▁batch 3.203125
es 0.0299072265625
▁of 0.322265625
▁APIs 1.28515625
▁and 0.326904296875
▁drug 0.037109375
▁products 0.0179901123046875
▁for 0.87841796875
▁clin 0.65478515625
ical 0.00019407272338867188
▁tri 0.32177734375
als 1.8835067749023438e-05
▁and 0.73291015625
▁stability 4.3984375
▁testing 1.7353515625
. 0.0904541015625
<0x0A> 0.86767578125
<0x0A> 0.05316162109375
PR 1.9462890625
& 0.0009174346923828125
D 0.0005774497985839844
▁can 3.833984375
▁decrease 7.51171875
▁development 2.826171875
▁time 2.28125
▁and 0.6064453125
▁increase 2.37109375
▁pipeline 8.15625
▁output 4.8125
▁in 3.9765625
▁several 3.728515625
▁ways 0.01331329345703125
. 0.17138671875
▁First 1.1513671875
ly 1.193359375
, 0.0013027191162109375
▁beginning 11.5078125
▁process 1.0029296875
▁research 1.1982421875
▁and 0.8671875
▁development 0.054046630859375
▁early 1.1865234375
▁in 0.7392578125
▁the 0.203369140625
▁drug 0.433349609375
▁discovery 1.61328125
▁phase 1.953125
▁allows 1.63671875
▁for 0.50244140625
▁parallel 2.22265625
▁processing 0.58740234375
▁which 6.32421875
▁saves 3.65234375
▁time 0.0985107421875
. 0.65185546875
▁Second 0.327880859375
ly 0.004261016845703125
, 0.0012531280517578125
▁using 3.1640625
▁tools 6.3828125
▁like 1.626953125
▁computational 2.69140625
▁model 1.140625
ing 0.0004706382751464844
▁and 0.452880859375
▁continuous 5.50390625
▁processing 2.14453125
▁can 0.705078125
▁acceler 3.2421875
ate 0.0004303455352783203
▁process 2.25
▁research 3.53125
. 2.5
▁Third 1.1630859375
ly 0.002471923828125
, 0.0022525787353515625
▁quality 6.23046875
▁by 0.163330078125
▁design 0.0030803680419921875
▁( 0.1663818359375
Q 0.00046181678771972656
b 0.00850677490234375
D 4.279613494873047e-05
) 0.030242919921875
▁and 1.388671875
▁design 0.95751953125
▁of 0.04278564453125
▁experiments 0.1151123046875
▁( 0.036346435546875
Do 0.7919921875
E 0.0286407470703125
) 0.0040740966796875
▁help 4.16796875
▁optimize 2.025390625
▁processes 1.51171875
▁faster 5.046875
▁while 4.921875
▁building 7.7421875
▁quality 3.50390625
▁into 0.1646728515625
▁the 0.344970703125
▁process 0.6455078125
. 0.80712890625
▁Four 1.7666015625
th 0.0001150369644165039
ly 0.01470184326171875
, 0.0026988983154296875
▁util 4.171875
izing 0.02032470703125
▁platform 5.3203125
▁techn 0.290283203125
ologies 6.67572021484375e-05
▁can 1.474609375
▁exped 4.37890625
ite 0.006877899169921875
▁the 0.97802734375
▁development 0.59521484375
▁of 0.19482421875
▁similar 3.58203125
▁mole 2.271484375
cules 0.01151275634765625
. 0.6982421875
▁Finally 0.9560546875
, 0.001495361328125
▁se 8.40625
am 0.25634765625
less 0.14697265625
▁technology 3.056640625
▁transfer 0.150390625
▁from 1.0380859375
▁PR 5.3046875
& 0.003345489501953125
D 0.00047588348388671875
▁to 0.022308349609375
▁manufact 0.71533203125
uring 0.0009427070617675781
▁ens 1.734375
ures 7.200241088867188e-05
▁efficient 2.6796875
▁scale 2.056640625
- 0.08868408203125
up 0.002025604248046875
▁and 0.6728515625
▁reduced 5.03515625
▁tim 1.984375
elines 0.14794921875
. 0.1175537109375
<0x0A> 0.2216796875
<0x0A> 0.06390380859375
An 5.44921875
▁example 1.3583984375
▁of 0.049285888671875
▁how 2.283203125
▁PR 0.30224609375
& 0.0013685226440429688
D 0.0011310577392578125
▁solved 12.234375
▁a 0.33349609375
▁manufact 2.392578125
uring 0.00664520263671875
▁problem 0.83984375
▁is 0.70654296875
▁with 2.99609375
▁the 0.77734375
▁development 1.521484375
▁of 0.038818359375
▁a 2.23046875
▁modified 6.3203125
- 1.16796875
release 0.004302978515625
▁dos 4.0703125
age 0.006999969482421875
▁form 0.0181121826171875
▁of 1.02734375
▁an 2.2421875
▁API 3.025390625
▁that 3.38671875
▁showed 6.57421875
▁poor 1.875
▁flow 5.34765625
▁properties 0.75
▁and 2.888671875
▁content 6.875
▁uniform 0.01129913330078125
ity 0.0013446807861328125
▁issues 4.2734375
. 0.6171875
▁The 1.2861328125
▁PR 1.6015625
& 0.0037288665771484375
D 0.0008587837219238281
▁team 0.135986328125
▁used 1.6123046875
▁Q 2.88671875
b 0.004878997802734375
D 0.00010633468627929688
▁to 1.2421875
▁study 5.03125
▁the 0.361328125
▁impact 2.86328125
▁of 0.0259552001953125
▁raw 5.6796875
▁materials 1.3486328125
▁and 0.923828125
▁processing 2.60546875
▁parameters 0.84912109375
▁on 0.10638427734375
▁the 0.56640625
▁critical 5.19140625
▁quality 0.1519775390625
▁attributes 0.03765869140625
▁( 0.71142578125
C 0.01496124267578125
Q 0.0005936622619628906
As 0.059173583984375
) 0.3251953125
▁of 0.1627197265625
▁the 0.0654296875
▁API 0.80908203125
. 0.166748046875
▁They 0.49609375
▁identified 1.654296875
▁the 1.0078125
▁source 3.201171875
▁of 0.037506103515625
▁vari 1.4013671875
ability 0.0017862319946289062
▁and 0.77783203125
▁adjust 4.69140625
ed 0.00212860107421875
▁the 0.239501953125
▁process 1.1630859375
▁parameters 1.158203125
▁accordingly 1.7587890625
▁to 1.8076171875
▁achieve 1.7724609375
▁the 1.56640625
▁target 3.091796875
▁product 2.607421875
▁profile 0.1661376953125
. 0.6650390625
▁Add 9.1171875
itional 0.06427001953125
▁experiments 3.732421875
▁at 5.9453125
▁pilot 2.869140625
▁scale 0.666015625
▁valid 2.05859375
ated 0.00020241737365722656
▁the 0.106201171875
▁robust 3.275390625
ness 0.0293731689453125
▁of 0.08795166015625
▁the 0.01361083984375
▁optimized 0.486083984375
▁process 0.0771484375
. 0.66796875
▁The 1.87109375
▁implementation 6.28125
▁of 0.006183624267578125
▁the 1.8408203125
▁new 2.494140625
▁process 0.414794921875
▁and 4.73046875
▁specific 4.6953125
ations 0.0018091201782226562
▁enabled 3.248046875
▁the 0.5400390625
▁successful 2.841796875
▁development 2.6640625
▁of 0.2401123046875
▁the 0.63720703125
▁modified 0.96630859375
- 0.033538818359375
release 0.0013446807861328125
▁product 2.755859375
. 0.435546875
<0x0A> 0.1956787109375
<0x0A> 0.0458984375
In 2.525390625
▁summary 1.09765625
, 0.0014638900756835938
▁PR 0.279541015625
& 0.00019359588623046875
D 0.0001647472381591797
▁plays 0.66015625
▁an 2.224609375
▁integral 2.712890625
▁role 0.0172576904296875
▁in 0.00244140625
▁bringing 4.64453125
▁a 2.458984375
▁new 0.4736328125
▁drug 0.290283203125
▁to 0.146240234375
▁market 0.13671875
▁by 0.732421875
▁developing 1.72265625
▁and 3.482421875
▁optim 0.446533203125
izing 0.00025773048400878906
▁manufact 0.8759765625
uring 6.771087646484375e-05
▁processes 0.0009679794311523438
▁in 3.29296875
▁parallel 0.06500244140625
▁with 0.0445556640625
▁clin 0.87548828125
ical 5.3763389587402344e-05
▁development 0.193603515625
. 0.05914306640625
▁ 5.48046875
▁Using 5.1875
▁modern 5.30859375
▁tools 0.295166015625
▁and 0.58447265625
▁platforms 4.546875
, 0.36767578125
▁PR 0.400146484375
& 9.298324584960938e-05
D 0.0002493858337402344
▁can 0.244873046875
▁significantly 3.51171875
▁acceler 1.6943359375
ate 0.0002524852752685547
▁ph 7.515625
arma 0.0017595291137695312
ce 0.00982666015625
ut 5.0067901611328125e-06
ical 5.173683166503906e-05
▁development 0.365234375
▁tim 0.456787109375
elines 0.0021076202392578125
▁and 1.1259765625
▁boost 5.37109375
▁pipeline 0.425537109375
▁product 3.380859375
ivity 0.001415252685546875
. 0.040679931640625
▁With 6.4296875
▁the 1.611328125
▁increasing 2.298828125
▁complexity 1.5859375
▁of 0.1707763671875
▁drug 0.94189453125
▁mole 1.84375
cules 0.0004601478576660156
▁and 0.560546875
▁delivery 7.09765625
▁techn 2.904296875
ologies 3.3020973205566406e-05
, 0.01406097412109375
▁the 1.3525390625
▁role 0.771484375
▁of 0.0223541259765625
▁PR 0.0439453125
& 5.900859832763672e-05
D 0.0003592967987060547
▁will 1.3623046875
▁become 2.107421875
▁even 0.289794921875
▁more 0.00037384033203125
▁cru 1.24609375
cial 4.172325134277344e-06
▁to 4.01171875
▁translate 9.03125
▁innov 1.4033203125
ative 0.342041015625
▁ther 3.75
ap 0.0006837844848632812
ies 4.494190216064453e-05
▁to 3.701171875
▁patients 0.7177734375
. 0.84130859375
